Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

On Nov. 10, 2010, the Food and Drug Administration (FDA) approved tessamorelin (Egrifta®) to treat HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs (visceral body fat).

FDA Notifications